SBIR/STTR Research Award

Evaluation of oral oleocanthal to prevent and/or treat Alzheimer's disease and related dementias

Award identifier 39afe2f029df3017d0fa4cd2b6451527785d55308cb2a2c6921fb48da970f721Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$336,647

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Oleolive, Inc.
Proposal award date
2018-09-30
Contract end date
2021-05-31
UEI
DSBCG7NS87J3
Solicitation number
PAS18-187
Topic code
NIA

Research abstract

PROJECT SUMMARY Alzheimer s diseaseADis a progressive neurodegenerative disorder of the elderly that afflicts aboutmillion patients globally and overmillion Americans in the USDespite the considerable research effort to preventtreator cure the diseaseeffective strategies remain lackingThe accumulation of amyloidAin the brain blood vessels can result in the development of cerebral amyloid angiopathyCAACAA is a pathological feature present concomitantly with AD at a high frequencyhighlighting a potentially important role for vascular Ain dementias such as ADCurrently no treatment is available to slow or stop the progression of CAA and ADThe purpose of this application is to evaluate oleocanthalOCa natural phenolic compound isolated from extra virgin olive oilas a novel molecule with neuroprotective effects against AD in a mouse modelThe overall goal of this project is to generate data to inform the commercialization pathways Oleolive will follow for OC and guide the company development strategy to be proposed in a Phase II SBIRThe central hypothesis is that low dose nano emulsions of OC in water fed to mice will be effective as a preventive and therapeutic in mouse models of ADThis hypothesis will be tested by pursuing the following specific aimsAimPerform dose dependent studies to determine the optimum protective dose of orally administered OCThis Aim will be examined via the Sub Aimsaevaluate OC effect on BBB integrityvascular and cerebral Aloadand synaptic integrityand bevaluate OC effect on efficacy and toxicity biomarkersAimEvaluate the effect of orally administered OC on metabolic and behavior phenotypesMethods and techniques to be used to accomplish the above aims include in vivo studies in AD mouse modelbiochemical analysismicrovessels isolation from mice brainstoxicity and histopathology studiesand metabolic and behavior phenotype studiesFindings from this work are expected to confirm OC as a novel molecule to prevent and or treat AD and related dementias and would support and advance OC therapeutic development toward clinical trials NARRATIVE AD and AD related dementiasADRDconstitute a major public health problem and have been reported to triple healthcare costsPreliminary studies show oleocanthal demonstrates promising effects against ADThe proposed project will determine the optimal dose of oleocanthal for safety and efficacy in an AD mouse modeland position oleocanthal as a potential preventive and or treatment for AD and ADRD

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

8 SBIR/STTR records share this UEI (2018–2025). Reported award amounts total $5,248,395. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.